Phase 2 study of erlotinib in combination with linsitinib (OSI-906) or placebo in chemotherapy-naive patients with non–small-cell lung cancer and activating epidermal growth factor receptor mutations Journal Article
| Authors: | Leighl, N. B.; Rizvi, N. A.; de Lima, L. G. Jr; Arpornwirat, W.; Rudin, C. M.; Chiappori, A. A.; Ahn, M. J.; Chow, L. Q. M.; Bazhenova, L.; Dechaphunkul, A.; Sunpaweravong, P.; Eaton, K.; Chen, J.; Medley, S.; Poondru, S.; Singh, M.; Steinberg, J.; Juergens, R. A.; Gadgeel, S. M. |
| Article Title: | Phase 2 study of erlotinib in combination with linsitinib (OSI-906) or placebo in chemotherapy-naive patients with non–small-cell lung cancer and activating epidermal growth factor receptor mutations |
| Abstract: | Micro-Abstract This was a phase II study of linsitinib plus erlotinib versus placebo plus erlotinib in chemotherapy-naive patients with epidermal growth factor receptor-mutation positive, advanced, non–small-cell lung cancer. Linsitinib plus erlotinib resulted in inferior outcomes compared with erlotinib alone. Linsitinib combination was associated with increased adverse events that led to decreased erlotinib exposure. Results highlight the complexity of targeting insulin-like growth factor-1 receptor signaling. © 2016 Elsevier Inc. |
| Keywords: | tyrosine kinase inhibitor; first-line therapy; combination; epidermal growth factor receptor inhibitor; insulin-like growth factor-1 inhibitor |
| Journal Title: | Clinical Lung Cancer |
| Volume: | 18 |
| Issue: | 1 |
| ISSN: | 1525-7304 |
| Publisher: | Elsevier Inc. |
| Date Published: | 2017-01-01 |
| Start Page: | 34 |
| End Page: | 42.e2 |
| Language: | English |
| DOI: | 10.1016/j.cllc.2016.07.007 |
| PROVIDER: | scopus |
| PUBMED: | 27686971 |
| PMCID: | PMC5474312 |
| DOI/URL: | |
| Notes: | Article -- Export Date: 2 February 2017 -- Source: Scopus |
